title: Anti-inflammatory activity of antifungal preparations.
abstract: BACKGROUND
  Although steroid/antifungal combination medications are used extensively, they are associated with potential disadvantages. Antifungal preparations possessing inherent anti-inflammatory activity, leading to rapid symptomatic relief while providing mycologic cure, would be very useful.
  
  
  OBJECTIVE
  Our purpose was to investigate the anti-inflammatory activity of proprietary antifungal preparations in an in vivo, human experimental model.
  
  
  METHODS
  Using a double-blind, controlled protocol, we assessed the comparative ability of antifungal preparations to suppress the expected delayed erythema response following in vivo human exposure to ultraviolet B (UVB) irradiation generated by a solar stimulator.
  
  
  RESULTS
  Currently available allylamine preparations and ciclopirox olamine proved to be the most anti-inflammatory, while ketoconazole was intermediate in anti-inflammatory activity under these experimental conditions. These agents were superior to oxiconazole, econazole, and 2.5% hydrocortisone.
  
  
  CONCLUSIONS
  Some antifungal preparations possess inherent anti-inflammatory activity, although the exact mechanism remains uncertain.
authors.affiliation: Department of Dermatology, Baylor College of Medicine, Houston, Texas, USA.
authors.forename: T
authors.initials: T
authors.lastname: Rosen
authors.forename: B J
authors.initials: BJ
authors.lastname: Schell
authors.forename: I
authors.initials: I
authors.lastname: Orengo
mesh_terms: D000328:Adult; D000499:Allylamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018890:Chemoprevention; D000077768:Ciclopirox; D004311:Double-Blind Method; D004464:Econazole / Q000627:therapeutic use; D004890:Erythema / Q000209:etiology / Q000517:prevention & control; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007093:Imidazoles / Q000627:therapeutic use; D007654:Ketoconazole / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D000077291:Terbinafine; D014466:Ultraviolet Rays / Q000009:adverse effects
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000935:Antifungal Agents; D007093:Imidazoles; D009281:Naphthalenes; D011728:Pyridones; D000077768:Ciclopirox; D000499:Allylamine; C029178:naftifine; D004464:Econazole; C022155:oxiconazole; D000077291:Terbinafine; D007654:Ketoconazole; D006854:Hydrocortisone